Published in Sci Rep on August 07, 2017
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol (2013) 4.84
Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2010) 3.03
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost (2010) 2.47
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost (2012) 2.24
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol (2014) 2.17
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet (2008) 1.71
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost (2013) 1.21
Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation (2011) 1.10
A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost (2011) 1.00
A novel quantitative assessment of whole blood thrombogenicity in patients treated with a non-vitamin K oral anticoagulant. Int J Cardiol (2015) 0.96
Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost (2013) 0.96
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost (2014) 0.95
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost (2014) 0.95
A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res (2011) 0.91
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke (2014) 0.87
Total Thrombus-Formation Analysis System (T-TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc (2016) 0.85
Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol (2013) 0.83
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. J Am Coll Cardiol (2016) 0.83
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost (2016) 0.80
Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thromb Res (2013) 0.80
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost (2014) 0.78
Letter by Sueta et al Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". Circulation (2016) 0.78
Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin. Thromb Res (2015) 0.77
Hemoglobin A1c predicts heart failure hospitalization independent of baseline cardiac function or B-type natriuretic peptide level. Diabetes Res Clin Pract (2014) 0.86
The accuracy of central blood pressure waveform by novel mathematical transformation of non-invasive measurement. Int J Cardiol (2015) 0.84
Effect of Discontinuation of Prednisolone Therapy on Risk of Cardiac Mortality Associated With Worsening Left Ventricular Dysfunction in Cardiac Sarcoidosis. Am J Cardiol (2015) 0.79
Validation of the high mortality rate of Malnutrition-Inflammation-Atherosclerosis syndrome: -Community-based observational study. Int J Cardiol (2016) 0.78
Circulating Omega-6, But Not Omega-3 Polyunsaturated Fatty Acids, Are Associated with Clinical Outcomes in Patients with Acute Decompensated Heart Failure. PLoS One (2016) 0.78
Association of estimated central blood pressure measured non-invasively with pulse wave velocity in patients with coronary artery disease. Int J Cardiol Heart Vasc (2015) 0.78
Usefulness of Geriatric Nutritional Risk Index for Assessing Nutritional Status and Its Prognostic Impact in Patients Aged ≥65 Years With Acute Heart Failure. Am J Cardiol (2016) 0.77
Prognostic value of malnutrition assessed by Controlling Nutritional Status score for long-term mortality in patients with acute heart failure. Int J Cardiol (2016) 0.76
Successful balloon pulmonary angioplasty with gadolinium contrast media for a patient with chronic thromboembolic pulmonary hypertension and iodine allergy. Respir Med Case Rep (2016) 0.75
Persistent increase in cardiac troponin T at hospital discharge predicts repeat hospitalization in patients with acute decompensated heart failure. PLoS One (2017) 0.75
Letter to Editor: Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspective. Int J Cardiol (2017) 0.75
Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure. Eur J Heart Fail (2016) 0.75
Early development of acute kidney injury is an independent predictor of in-hospital mortality in patients with acute myocardial infarction. J Cardiol (2016) 0.75
A rare case of long-term survival with idiopathic dilatation of the pulmonary artery. Int J Cardiol (2016) 0.75
Transdistal Bypass and Collateral Approach for Infrapopliteal Chronic Total Occlusion Intervention. JACC Cardiovasc Interv (2016) 0.75
Impact of Elevated End-Diastolic Pulmonary Regurgitation Gradient on Worse Clinical Outcomes in Hospitalized Patients With Heart Failure. Am J Cardiol (2016) 0.75
Progression of Intimal Hyperplasia and Multiple-Channel Formation After Fogarty Thrombectomy: Insight Into Vasculopathy From Optical Coherence Tomography and Intravascular Ultrasound Findings. JACC Cardiovasc Interv (2015) 0.75
Stenting for Juxtarenal Abdominal Aortic Occlusion. JACC Cardiovasc Interv (2016) 0.75
Prevalence, determinants, and prognostic significance of delirium in patients with acute heart failure. Int J Cardiol (2016) 0.75
Impact of target vessel on long-term cardiac mortality after successful chronic total occlusion percutaneous coronary intervention: Insights from a Japanese multicenter registry. Int J Cardiol (2017) 0.75
Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail (2017) 0.75
New aspects of onco-cardiology. Int J Cardiol (2016) 0.75
Clinical significance of fecal occult blood screening in patients before percutaneous coronary intervention. Int J Cardiol (2014) 0.75
Potential of Using Occult Collateral Vessels for Transcollateral Intervention in Infrapopliteal Chronic Occlusion. Ann Vasc Surg (2016) 0.75